Valuation: EnteroMedics Inc

Market Cap 15.3M 13.21M 12.42M 11.29M 21.23M 1.46B 21.58M 146M 56.89M 733M 57.45M 56.2M 2.43B P/E 2026 *
-3.09x
P/E 2027 * -2.38x
Enterprise Value 15.3M 13.21M 12.42M 11.29M 21.23M 1.46B 21.58M 146M 56.89M 733M 57.45M 56.2M 2.43B EV / Sales 2026 *
102x
EV / Sales 2027 * 61.2x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 150K 130K 122K 111K 208K 14.34M 212K 1.43M 558K 7.18M 563K 551K 23.87M 250K 216K 203K 185K 347K 23.91M 353K 2.38M 930K 11.97M 939K 918K 39.78M
Net income -4.89M -4.22M -3.97M -3.61M -6.79M -468M -6.9M -46.5M -18.18M -234M -18.36M -17.96M -778M -7.77M -6.71M -6.31M -5.73M -10.78M -743M -10.96M -73.88M -28.89M -372M -29.17M -28.54M -1.24B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-